Search Prime Grants

UG1HL138645

Cooperative Agreement

Overview

Grant Description
Mount Sinai Core Clinical Consortium for the BMT Clinical Trials Network.
Awardee
Icahn School Of Medicine At Mount Sinai
Funding Goals
THE DIVISION OF BLOOD DISEASES AND RESOURCES SUPPORTS RESEARCH AND RESEARCH TRAINING ON THE PATHOPHYSIOLOGY, DIAGNOSIS, TREATMENT, AND PREVENTION OF NON-MALIGNANT BLOOD DISEASES, INCLUDING ANEMIAS, SICKLE CELL DISEASE, THALASSEMIA, LEUKOCYTE BIOLOGY, PRE-MALIGNANT PROCESSES SUCH AS MYELODYSPLASIA AND MYELOPROLIFERATIVE DISORDERS, HEMOPHILIA AND OTHER ABNORMALITIES OF HEMOSTASIS AND THROMBOSIS, AND IMMUNE DYSFUNCTION. FUNDING ENCOMPASSES A BROAD SPECTRUM OF HEMATOLOGIC INQUIRY, RANGING FROM STEM CELL BIOLOGY TO MEDICAL MANAGEMENT OF BLOOD DISEASES AND TO ASSURING THE ADEQUACY AND SAFETY OF THE NATION'S BLOOD SUPPLY. PROGRAMS ALSO SUPPORT THE DEVELOPMENT OF NOVEL CELL-BASED THERAPIES TO BRING THE EXPERTISE OF TRANSFUSION MEDICINE AND STEM CELL TECHNOLOGY TO THE REPAIR AND REGENERATION OF HUMAN TISSUES AND ORGANS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.
Grant Program (CFDA)
93.837 - Cardiovascular Diseases Research
Awarding / Funding Agency
National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]
Place of Performance
New York, New York 100296504 United States
Geographic Scope
Single Zip Code
Related Opportunity
The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional) (RFA-HL-24-010)
Analysis Notes
Amendment Since initial award the End Date has been extended from 06/30/24 to 06/30/31 and the total obligations have increased 781% from $193,233 to $1,701,765.
Icahn School Of Medicine At Mount Sinai was awarded Mount Sinai Core Clinical Consortium for the BMT Clinical Trials Network Cooperative Agreement UG1HL138645 worth $1,701,765 from National Heart Lung and Blood Institute in July 2017 with work to be completed primarily in New York New York United States. The grant has a duration of 14 years and was awarded through assistance program 93.837 Cardiovascular Diseases Research. The Cooperative Agreement was awarded through grant opportunity The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional).

Status
(Ongoing)

Last Modified 8/20/25

Period of Performance
7/27/17
Start Date
6/30/31
End Date
61.0% Complete

Funding Split
$1.7M
Federal Obligation
$0.0
Non-Federal Obligation
$1.7M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to UG1HL138645

Subgrant Awards

Disclosed subgrants for UG1HL138645

Transaction History

Modifications to UG1HL138645

Additional Detail

Award ID FAIN
UG1HL138645
SAI Number
UG1HL138645-2301565699
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Funding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Awardee UEI
C8H9CNG1VBD9
Awardee CAGE
1QSQ9
Performance District
NY-13
Senators
Kirsten Gillibrand
Charles Schumer

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Heart, Lung, and Blood Institute, National Institutes of Health, Health and Human Services (075-0872) Health research and training Grants, subsidies, and contributions (41.0) $1,594,873 100%
Modified: 8/20/25